Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research.
from Top Health News – ScienceDaily http://ift.tt/2smR9Ly
from Tumblr http://ift.tt/2se75QX
No comments:
Post a Comment